MYC、BCL2和BCL6基因额外拷贝与弥漫性大B细胞淋巴瘤患者的结局
该回顾性单中心研究纳入144例弥漫性大B细胞淋巴瘤(DLBCL)患者,比较经典双打击/三打击高危B细胞淋巴瘤(DHL)、MYC额外拷贝伴BCL2和/或BCL6异常但不满足HGBL标准(EC组)及无异常(WT组)的预后。中位随访36个月,WT与EC组2年无事件生存率相似(77% vs 82%),DHL组为63%。EC组接受R-CHOP治疗结局与WT组相似。
要点
- EC组与WT组不良基线特征频率相似,DHL组显著更常见。
- 2年EFS:WT组77%、EC组82%、DHL组63%。
- 接受R-CHOP治疗的EC组结局与WT组相似。
核心结论
- 伴有MYC、BCL2和BCL6基因额外拷贝的DLBCL患者结局与HGBL不同,对标准R-CHOP治疗反应良好。
研究设计与样本
- 回顾性单中心研究,共纳入144例DLBCL患者,分为DHL组46例、EC组55例和WT组43例。
主要发现
- 中位随访36个月,2年无事件生存率:WT组77%(95%CI 65-90)、EC组82%(95%CI 72-93)、DHL组63%(95%CI 51-79)。
- 2年总生存率:WT组86%(95%CI 76-97)、EC组89%(95%CI 81-98)、DHL组74%(95%CI 62-88)。
- EC组与WT组不良基线特征频率相似,DHL组显著更常见。
- 接受R-CHOP治疗的EC组结局与WT组相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade B-cell lymphoma (HGBL) with translocations involving MYC and BCL2 or BCL6 comprises ∼10% of cases of diffuse large B-cell lymphoma (DLBCL) and carries a poor prognosis. The incidence, prognosis, and optimal therapy for DLBCL harboring extra copies of the genes MYC, BCL2, and BCL6, rather than their genetic translocations, are unknown. In this retrospective, single-center study we identified 144 DLBCL cases including 46 patients with classic HGBL with double-hit or triple-hit chromosomal translocations (DHL), 55 with extra copies of MYC in addition to aberrations (extra copies or translocations) of BCL2 and/or BCL6 but did not meet the criteria for HGBL (EC group), and 43 without any aberrations of MYC, BCL2, or BCL6 (wild type [WT]). Unfavorable baseline characteristics had similar frequency in the EC and WT groups, but were significantly more prevalent in the DHL group. With a median follow-up of 36 months, the 2-year event-free survival (EFS) was similar between the WT and EC groups at 77% (95% confidence interval [CI], 65-90) and 82% (95% CI, 72-93), respectively. In contrast, the 2-year EFS of the DHL group was 63% (95% CI, 51-79). The 2-year overall survival in the WT, EC, and DHL groups was 86% (95% CI, 76-97), 89% (95% CI, 81-98), and 74% (95% CI, 62-88), respectively. Among patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), the EC group had outcomes similar to those of the WT group. Our results indicate that patients with DLBCL with extra gene copies of MYC, BCL2, and BCL6 fare differently from those with HGBL and respond well to standard R-CHOP therapy.
引用
- Sermer D, Bobillo S, Dogan A, et al. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32722781. doi:10.1182/bloodadvances.2020001551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。